Literature DB >> 8869933

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Q Yi1, A Osterborg.   

Abstract

In this paper, the results of some recent studies on idiotype-specific T cells in human multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are discussed. By using different in vitro measurements such as 3H-thymidine incorporation and ELI-SPOT assay, idiotype-specific T cells have been demonstrated in most of MM and MGUS patients. Based on the cytokine-secretion profiles, idiotype-specific T cells were found to comprise both Th1 and Th2 cells. A Th1 type immunity was found preferentially in indolent disease and a Th2-like response predominated in advanced MM, suggesting a specific T-cell regulation of the tumor B-cell clone. The mode of T-cell recognition of id determinants on M-components has been studied. We found that idiotype-specific T cells recognized processed id determinants presented by MHC class II (HLA-DR) molecules on APC. B cells were much more efficient APC than monocytes. With the aim to induce or to amplify an idiotype-specific T-cell response, we have immunized MM patients with the autologous M-component precipitated in aluminum. Three out of the five patients showed an induction of specific cellular and humoral immunity. Nevertheless, the role for such immunity in controlling the tumor clone remains to be established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869933     DOI: 10.1007/bf02988835

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  69 in total

1.  Human TH1 and TH2 subsets: doubt no more.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1991-08

2.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.

Authors:  C Czerkinsky; G Andersson; H P Ekre; L A Nilsson; L Klareskog; O Ouchterlony
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

Review 3.  Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.

Authors:  H Mellstedt; G Holm; M Björkholm
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

4.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

5.  Idiotypic vaccination as a treatment for a B cell lymphoma.

Authors:  A J George; S G Folkard; T J Hamblin; F K Stevenson
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

6.  A monoclonal antiidiotypic antibody to MOPC 315 IgA inhibits the growth of MOPC 315 myeloma cells in vitro.

Authors:  J Mahony; A Bose; D Cowdrey; T Nusair; M Lei; J Harris; A Marks; R Baumal
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

7.  In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy.

Authors:  T Paglieroni; M R MacKenzie
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

8.  Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests.

Authors:  A Osterborg; Q Yi; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Br J Haematol       Date:  1995-01       Impact factor: 6.998

Review 9.  Immunoglobulin-specific suppressor T cells.

Authors:  R G Lynch
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

10.  T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia.

Authors:  J F San Miguel; M D Caballero; M Gonzalez
Journal:  Am J Hematol       Date:  1985-11       Impact factor: 10.047

View more
  10 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 3.  Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status.

Authors:  B Björkstrand
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

4.  Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

Authors:  Sivasubramanian Baskar; Carol B Kobrin; Larry W Kwak
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 5.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

6.  Multiple myeloma: VI International Workshop, June 14-18, 1997, Boston, Massachusetts, USA.

Authors:  S Bergenbrant
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

7.  Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs.

Authors:  F Tian; J Li; Y Li; S Luo
Journal:  Blood Cancer J       Date:  2012-06-15       Impact factor: 11.037

8.  Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.

Authors:  Jie Ma; Liqiang Zhou; Daqing Wang
Journal:  Jpn J Cancer Res       Date:  2002-01

Review 9.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

10.  Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2-myeloma cell interaction.

Authors:  Faqing Tian; Bo Lu; Ziren Chen; Junru Liu; Delan Ji; Juheng Li; Meiqin Tang; Wei Zhu; Juan Li
Journal:  BMC Cancer       Date:  2019-12-23       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.